Jurgen Mattern
Overview
Explore the profile of Jurgen Mattern including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
663
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zhang C, Wenger T, Mattern J, Ilea S, Frey C, Gutwein P, et al.
Cancer Biol Ther
. 2007 Jan;
6(2):278-87.
PMID: 17224649
Background: Glucocorticoids have been used widely in conjunction with cancer therapy due to their ability to induce apoptosis in hematological cells and to prevent nausea and emesis. However, recent data...
12.
Zhang C, Kolb A, Buchler P, Cato A, Mattern J, Rittgen W, et al.
BMC Cancer
. 2006 Mar;
6:61.
PMID: 16539710
Background: Chemotherapy for pancreatic carcinoma often has severe side effects that limit its efficacy. The glucocorticoid (GC) dexamethasone (DEX) is frequently used as co-treatment to prevent side effects of chemotherapy...
13.
Zhang C, Marme A, Wenger T, Gutwein P, Edler L, Rittgen W, et al.
Int J Oncol
. 2006 Jan;
28(2):551-8.
PMID: 16391812
The glucocorticoid dexamethasone is frequently used as a co-treatment in cytotoxic cancer therapy, e.g. to prevent nausea, to protect normal tissue or for other reasons. While the potent pro-apoptotic properties...
14.
Mattern J, Volm M
Anticancer Res
. 2005 Mar;
24(6):4243-6.
PMID: 15736479
To evaluate the relationship between cell proliferation and apoptosis during progression of lung carcinomas, immunohistochemistry for proliferating cell nuclear antigen (PCNA) and the in situ end labelling (TUNEL) method for...
15.
Okouoyo S, Herzer K, Ucur E, Mattern J, Krammer P, Debatin K, et al.
Int J Cancer
. 2003 Dec;
108(4):580-7.
PMID: 14696123
Non small cell lung carcinoma (NSCLC) is a highly lethal malignancy that often becomes resistant to chemotherapy. To determine whether alterations in apoptotic signaling might contribute to such resistance, we...
16.
Mattern J
Anticancer Res
. 2003 Jun;
23(2C):1769-72.
PMID: 12820456
Drug resistance is an important problem in the treatment of patients with cancer. Tumors become resistant not only to the drugs used initially, but also to those to which they...
17.
Mattern J, Koomagi R, Volm M
Oncol Rep
. 2002 Oct;
9(6):1181-4.
PMID: 12375015
In order to study whether the presence of mechanisms of drug resistance is a characteristic unique to advanced lung cancer or occurs already early in the course of the disease,...
18.
Volm M, Koomagi R, Mattern J, Efferth T
Clin Exp Metastasis
. 2002 Aug;
19(5):385-90.
PMID: 12198766
The purpose of this investigation was to evaluate firstly whether different protein expression patterns exist in primary squamous cell lung carcinomas of patients with and without lymph node involvement and...
19.
Protein expression profiles of non-small cell lung carcinomas: correlation with histological subtype
Volm M, Koomagi R, Efferth T, Mattern J
Anticancer Res
. 2002 Aug;
22(4):2321-4.
PMID: 12174921
Of the four major subtypes of lung cancer, three subtypes, namely squamous cell lung carcinomas, adenocarcinomas and large cell carcinomas are usually combined within the larger group of non-small cell...
20.
Volm M, Koomagi R, Mattern J, Efferth T
Clin Cancer Res
. 2002 Jun;
8(6):1843-8.
PMID: 12060626
Purpose: Non-small cell lung cancer (NSCLC) is usually associated with a poor prognosis. Some patients survive their disease, and the underlying molecular mechanisms are still poorly understood. The purpose of...